1, China National Pharmaceutical Group is fully promoting the Group's five major platforms - modern logistics and distribution integrated operating platform, the integration of industry, academia and research platform for scientific and technological innovation, the integration of the international business platform, the platform for the medical and health care industry, and the platform for the integration of high-efficiency management, control and integration of synergistic platform. The Group is making every effort to promote the comprehensive construction of five platforms - modern logistics and distribution platform, international management platform, medical and healthcare industry platform, and efficient management, control and integration and synergy platform - to form five full-coverage networks - national pharmaceutical logistics distribution network, national pharmaceutical retail chain network, national narcotic drugs distribution network, national biological products marketing and cold chain distribution network, and national medical devices and consumables distribution network - and to promote the eleven businesses of the Group. --It promotes the comprehensive development of the Group's eleven major businesses - pharmaceutical modern logistics distribution, pharmaceutical retailing, biological products, chemical pharmaceuticals, modern Chinese medicine, diagnostic reagents and chemical reagents, scientific instruments and medical devices, pharmaceutical scientific research and engineering design, pharmaceutical international operation and overseas industry, pharmaceutical exhibition and media, and medical and healthcare industry, and constitutes an innovative enterprise with the pharmaceutical and healthcare industry as its core competitiveness. It constitutes an innovative enterprise with pharmaceutical and health industry as its core competitiveness. The Group has a pharmaceutical distribution network covering 31 provinces, autonomous regions and municipalities directly under the Central Government and 30 distribution centers in line with international standards. It is the largest biopharmaceutical R&D and production enterprise in China, and undertakes the production of more than 80% of the vaccines used in national immunization plan. The Group has established production bases and herb bases for biopharmaceuticals, narcotic psychotropic drugs, anti-infectives, anti-tumor drugs, cardio-cerebral and cerebrovascular drugs, respiratory drugs, etc., and possesses the strongest applied pharmaceutical research institutes and engineering design institutes in China.
2. Since the date of its establishment, China National Pharmaceutical Group has undertaken the tasks of centralized stockpiling, dispatching and supplying of national emergency and disaster relief medicines, Chinese herbal medicines, and medical devices, and China National Pharmaceutical Group Corporation has played an important role in safeguarding the people's life and health as well as the social stability in the critical periods and moments of crisis.
3. China National Pharmaceutical Group is the earliest, the most numerous and the most successful enterprise in China's pharmaceutical industry in cooperating with foreign capital. Since 1980, the pharmaceutical group has established 20 joint ventures with a number of internationally renowned pharmaceutical enterprises, such as China Otsuka Pharmaceutical Co., Ltd, Huarui Pharmaceutical Co., Ltd, Xi'an Janssen Pharmaceutical Co., Ltd, Sino-US Squibb Pharmaceutical Co., Ltd, and Suzhou Capsules Co. The pace of internationalization is accelerating.
4. In 2003, in the fight against SARS, China National Pharmaceutical Group Corporation, as a member of the Logistics Support Group of the National Command for the Prevention and Control of SARS, mobilized more than one hundred enterprises of the Group's system, and allocated medical supplies for the prevention and control of SARS to 22 provinces, autonomous regions and municipalities directly under the central government in the total amount of 130 million yuan; and supplied 170 million yuan of medical supplies for the prevention and control of SARS to the key areas, such as Beijing, and successfully accomplished the task of providing assistance to the Hong Kong Special Administrative Region, the Macao Special Administrative Region and the Hong Kong Special Administrative Region for 3000 yuan. The Central Government has successfully completed the organization and supply of more than 30 million yuan of medical supplies for the prevention and treatment of SARS to the Hong Kong SAR and the Macao SAR, and was awarded by the State-owned Assets Supervision and Administration Commission and the Development and Reform Commission.
5. In 2008, during the earthquake relief, China National Pharmaceutical Group responded quickly and went all out to complete the allocation of medical supplies for earthquake relief amounting to RMB 300 million, playing an important role at the critical moment.
6. In 2010, Sinopharm was recognized as a national innovative enterprise. In the same year, Sinopharm signed a strategic agreement to build the largest modernized Chinese medicine preparation industrial base in central China.
7. On December 15, 2012, the signing ceremony of China National Pharmaceutical Group's investment and holding of Modern Sunshine Physical Examination was held in Beijing, where China National Pharmaceutical Group and Beijing Modern Sunshine Health Science and Technology Company Limited jointly formed: Sinopharm Sunshine Health Science and Technology Company Limited, with a registered capital of 89.8 million yuan.
8, June 17, 2013, the establishment of Sinopharm Zhongyuan Hospital Management Co., Ltd. under the jurisdiction of five hospitals, for the Xinxiang Central Hospital, the Second People's Hospital of Xinxiang, the Third People's Hospital of Xinxiang, Xinxiang Hospital of Traditional Chinese Medicine, Xinxiang Maternity and Children's Healthcare Hospital.
9. In December 2017, the name of China National Pharmaceutical Group Corporation was changed to "China National Pharmaceutical Group Corporation".
10, January 2020, China National Pharmaceutical Group Corporation specifically set up a special fund of 1 billion yuan for the new coronavirus infection pneumonia epidemic. In April, selected by the State Council State-owned Assets Supervision and Administration Commission of the State Council "science and technology reform model enterprise" list. October 20, Sinopharm's new inactivated coronavirus vaccine is in the full sprint stage, biological vaccine research and development is the last kilometer of the long march, in the third phase of clinical trials to obtain safety and protection data, the vaccine can be marketed after review and approval.
11, October 20, 2020, Sinopharm's new crown inactivated vaccine is in the full sprint stage, biological vaccine research and development is the last kilometer left in the long march, in the phase III clinical trials to obtain safety and protective data, the vaccine can be marketed after review and approval.